Statistics Collaborative, Inc. (SCI) has proven experience on a range of issues related to HIV/AIDS, both in prevention and in treatment. We have worked with industry clients to provide Data Monitoring Committee (DMC) support for novel or reformulated treatment methods for HIV-infected patients.
Dr. Wittes has served on many committees dealing with HIV/AIDS both while she was employed by the National Heart, Lung, and Blood Institute (NHLBI) and during her tenure at SCI.
While a faculty member at the University of Minnesota, Dr. Bebchuk served as the study statistician for the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The trial studied an add-on cytokine therapy to boost immune-system response in HIV patients who were taking antiretrovirals.
Dr. Schumi studied resistance to antiretroviral drugs in her Ph.D. dissertation. In papers co-authored with her graduate advisors Victor DeGruttola and Gregory DiRienzo, she describes the methodology for analysis of high dimensional, sparse genotype and phenotype data.
Examples of SCI’s work in HIV/AIDS:
- Microbicides: The International Partnership for Microbicides (IPM) is a nonprofit product development partnership whose mission is to identify a safe and effective microbicide for use by women in the developing world for the prevention of HIV transmission. SCI has provided IPM with a wide range of statistical consultation, including sample size, protocol development, and adaptive design.
- HIV vaccine: Dr. Wittes served as a member of the Data Safety Monitoring Board (DSMB) for the Step Study that was sponsored jointly by NIAID and Merck.
- Anti-retrovirals: SCI has consulted for various companies who have developed antiretroviral drugs.
Examples of publications:
- Schumi J, DiRienzo AG, De Gruttola V. Testing for associations with missing high-dimensional categorical covariates. International Journal of Biostatistics 2008; 4:18.
- Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren J. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials 2006; 206:119-132.
- Schumi J, De Gruttola V. Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility. Stat Med 2008; 27:4740-4757.